Biocompatibles' drug-leaching beads are good, but not great, in HCC
This article was originally published in Clinica
Executive Summary
UK firm Biocompatibles International is touting trial data which suggest that its drug-eluting bead (DEB) technology may be a better liver cancer therapy than embolisation.